NFKB1 and Other metabolic disease: However, new and exciting NFκB-specific strategies are now being explored for cancer and metabolic diseases and will open new therapeutic opportunities for disease, including cell-specific and phase-specific oscillatory inhibition of NFκB in kidney injury.